{
  "id": 18634,
  "title": "STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more",
  "url": "https://urgent.news/2026/07/31/stat-pharmalittle-were-reading-about-a-novo-setback-support-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-31T13:28:17.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/07/31/novo-setback-fda-panel-endorses-replimune-melanoma-drug/"
  },
  "original_language": "en",
  "account": "The U.S. Food and Drug Administration (FDA) advisory panel has voted 10-to-3 in favor of recommending an experimental Replimune treatment for advanced melanoma, STAT reports. The recommendation hinges on the fact that Novo Nordisk, the pharmaceutical company behind RP1, an engineered viral immunotherapy, has presented sufficient data for the FDA to review. This decision, which comes after two previous rejections in 2022 and April 2023, could be seen as an indication of the FDA's new approach to assessing investigational drugs under the current administration. The approval of RP1 may signal a more permissive stance by the FDA, potentially setting a precedent for future evaluations of innovative therapies.",
  "summary": "An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice",
  "key_points": [
    "FDA panel votes 10-3 in favor of Replimune melanoma treatment",
    "Novo Nordisk's RP1 receives FDA review recommendation",
    "Approval signals FDA's new approach to experimental drugs"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 4,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "Capricor Duchenne cell therapy voted down by FDA panel",
        "url": "https://urgent.news/2026/07/29/capricor-duchenne-cell-therapy-voted-down-by-fda-panel",
        "published": "2026-07-29T21:31:00.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment",
        "url": "https://urgent.news/2026/07/30/stat-fda-expert-committee-votes-in-favor-of-replimunes-melanoma",
        "published": "2026-07-30T10:00:00.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "Replimune scores win as FDA advisors back melanoma treatment",
        "url": "https://urgent.news/2026/07/30/replimune-scores-win-as-fda-advisors-back-melanoma-treatment",
        "published": "2026-07-30T19:11:21.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}